Free Trial
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

Soleno Therapeutics logo
$55.06
-0.66 (-1.18%)
(As of 10/31/2024 ET)

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Key Stats

Today's Range
$54.10
$56.26
50-Day Range
$45.25
$56.29
52-Week Range
$21.30
$57.28
Volume
377,756 shs
Average Volume
465,970 shs
Market Capitalization
$1.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.86
Consensus Rating
Buy

Company Overview

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
86th Percentile Overall Score

SLNO MarketRank™: 

Soleno Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 172nd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Soleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Soleno Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Soleno Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($2.28) to ($2.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Soleno Therapeutics is -22.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Soleno Therapeutics is -22.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Soleno Therapeutics has a P/B Ratio of 10.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Soleno Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    20.63% of the float of Soleno Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Soleno Therapeutics has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in Soleno Therapeutics has recently increased by 15.12%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Soleno Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Soleno Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.63% of the float of Soleno Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Soleno Therapeutics has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in Soleno Therapeutics has recently increased by 15.12%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Soleno Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Soleno Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    10 people have searched for SLNO on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,178,033.00 in company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Soleno Therapeutics' insider trading history.
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Soleno Therapeutics price target raised to $73 from $65 at Oppenheimer
Soleno Therapeutics announces passing of former chairman Ernest Mario
See More Headlines

SLNO Stock Analysis - Frequently Asked Questions

Soleno Therapeutics' stock was trading at $40.25 at the beginning of the year. Since then, SLNO stock has increased by 36.8% and is now trading at $55.06.
View the best growth stocks for 2024 here
.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.06.

Soleno Therapeutics shares reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Top institutional shareholders of Soleno Therapeutics include Emerald Advisers LLC (0.94%), Emerald Mutual Fund Advisers Trust (0.70%), Allspring Global Investments Holdings LLC (0.42%) and Harbor Capital Advisors Inc. (0.11%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Bhatnagar Anish, Jack W Schuler, James H Mackaness and Kristen Yen.
View institutional ownership trends
.

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
8/07/2024
Today
10/31/2024
Next Earnings (Estimated)
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:SLNO
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.86
High Stock Price Target
$93.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+26.9%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Net Income
$-38,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.16 per share

Miscellaneous

Free Float
34,091,000
Market Cap
$1.84 billion
Optionable
Optionable
Beta
-1.45
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:SLNO) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners